• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

299 例原发性乳腺癌中孕激素受体异构体与 HER/ErbB 受体及其配体网络的关系。

Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.

机构信息

Département de Sénologie, Centre Oscar Lambret, Lille - France.

出版信息

Int J Biol Markers. 2012 Jul 19;27(2):e111-7. doi: 10.5301/JBM.2012.9198.

DOI:10.5301/JBM.2012.9198
PMID:22505232
Abstract

BACKGROUND

The effects of progesterone are mediated by 2 progesterone receptors (PR), PR-A and PR-B. Recently, several lines of evidence have suggested that reduced PR expression may result from hyperactivity in the signaling cascade generated by the HER/ErbB family. The aim of this study was to analyze the relationships between PR isoforms and the network of the HER/ErbB receptors and ligands in breast cancer.

PATIENTS AND METHODS

299 breast cancer samples from patients operated in our institute for locoregional disease between May 1989 and December 1991 were included. The mRNA expression of total PR-A+B isoforms and PR-B isoform were quantified by real time quantitative RT-PCR using TaqMan® probes.

RESULTS

mRNA levels of the PR isoforms positively correlated with protein levels of estradiol receptors (ER) and PR. The PR isoforms mRNA levels were inversely correlated with clinicopathological markers of tumor aggressiveness, such as SBR grading and lymph node involvement. The PR isoforms positively correlated with the mRNA levels of HER/ErbB receptors and ligands associated with a more differentiated phenotype (HER3, HER4, EGF, AREG, NRG3 and NRG4) while they correlated negatively with those associated with aggressiveness (EGFR, TGFa, HB-EGF, EREG, and NRG2).

CONCLUSION

Our results demonstrate the existence of strong correlations between mRNA levels of the PR isoforms, protein levels of hormone receptors, HER/ErbB receptors and ligands network, and thus suggest that crosstalks between PR and the HER family are a hallmark of breast cancer growth.

摘要

背景

孕激素的作用是通过 2 种孕激素受体(PR),即 PR-A 和 PR-B 来介导的。最近,有几条证据表明,PR 表达的减少可能是由于 HER/ErbB 家族信号级联的过度活跃所致。本研究的目的是分析 PR 同工型与乳腺癌中 HER/ErbB 受体和配体网络之间的关系。

患者和方法

纳入了 1989 年 5 月至 1991 年 12 月期间在我院接受局部区域性疾病手术的 299 例乳腺癌患者的样本。使用 TaqMan®探针通过实时定量 RT-PCR 定量测定总 PR-A+B 同工型和 PR-B 同工型的 mRNA 表达。

结果

PR 同工型的 mRNA 水平与雌激素受体(ER)和 PR 的蛋白水平呈正相关。PR 同工型的 mRNA 水平与肿瘤侵袭性的临床病理标志物呈负相关,如 SBR 分级和淋巴结受累。PR 同工型与与分化表型相关的 HER/ErbB 受体和配体(HER3、HER4、EGF、AREG、NRG3 和 NRG4)的 mRNA 水平呈正相关,而与侵袭性相关的 HER/ErbB 受体和配体(EGFR、TGFa、HB-EGF、EREG 和 NRG2)的 mRNA 水平呈负相关。

结论

我们的结果表明,PR 同工型的 mRNA 水平、激素受体的蛋白水平、HER/ErbB 受体和配体网络之间存在很强的相关性,这表明 PR 与 HER 家族之间的串扰是乳腺癌生长的一个标志。

相似文献

1
Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.299 例原发性乳腺癌中孕激素受体异构体与 HER/ErbB 受体及其配体网络的关系。
Int J Biol Markers. 2012 Jul 19;27(2):e111-7. doi: 10.5301/JBM.2012.9198.
2
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.人乳腺癌中的表皮生长因子受体(ErbB/HER)配体及其与受体的关系、生物病理特征和预后。
Ann Oncol. 2008 Jan;19(1):73-80. doi: 10.1093/annonc/mdm431. Epub 2007 Oct 24.
3
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.激素和HER-2受体对原发性早期乳腺癌初次手术后的短期预后
Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16.
4
Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.巴基斯坦北部乳腺癌的形态学特征及HER-2/neu与预后标志物的关联
J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103.
5
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.乳腺癌中雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2/neu,即C-erb B 2)反应模式与组织学分级、肿瘤大小及淋巴结状态的比较
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
6
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.孕激素受体通过依赖配体和不依赖配体的机制抑制乳腺癌细胞中的芳香化酶和炎症反应途径。
Mol Endocrinol. 2008 Aug;22(8):1812-24. doi: 10.1210/me.2007-0443. Epub 2008 May 15.
7
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.免疫组织化学与聚合酶链反应在评估乳腺癌雌激素受体(ER)、孕激素受体(PR)和Ki-67以及预测病理完全缓解方面的比较
BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.
8
Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.突尼斯乳腺癌中HER-2过表达与临床病理参数的相关性
World J Surg Oncol. 2008 Oct 22;6:112. doi: 10.1186/1477-7819-6-112.
9
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.1362例原发性可手术乳腺癌女性患者中肿瘤特征与免疫组化检测HER-2/neu之间的关联
J Clin Pathol. 2005 Jun;58(6):611-6. doi: 10.1136/jcp.2004.022772.
10
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.HER家族mRNA表达在高危早期乳腺癌中的预后意义评估:一项希腊合作肿瘤学组(HeCOG)验证研究
J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0.

引用本文的文献

1
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.肥胖相关性乳腺癌:危险因素分析与临床评估现状。
Adv Exp Med Biol. 2024;1460:767-819. doi: 10.1007/978-3-031-63657-8_26.
2
The inhibitory effect of trastuzumab on BT474 triple‑positive breast cancer cell viability is reversed by the combination of progesterone and estradiol.曲妥珠单抗对BT474三阳性乳腺癌细胞活力的抑制作用被孕酮和雌二醇的联合使用所逆转。
Oncol Lett. 2023 Nov 15;27(1):19. doi: 10.3892/ol.2023.14152. eCollection 2024 Jan.
3
PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
曲妥珠单抗辅助新辅助化疗治疗人表皮生长因子受体 2(HER2)阳性及淋巴结阳性乳腺癌的疗效与孕激素受体(PR)状态更相关,而非雌激素受体(ER)状态:中国真实世界回顾性研究。
World J Surg Oncol. 2023 Sep 18;21(1):296. doi: 10.1186/s12957-023-03178-4.
4
Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis.循环肿瘤游离DNA基因作为铂耐药卵巢癌诊断的预后基因标志物
Biomark Insights. 2022 Mar 28;17:11772719221088404. doi: 10.1177/11772719221088404. eCollection 2022.
5
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.ERBB4 的阴阳两面:肿瘤抑制蛋白和癌蛋白。
Pharmacol Rev. 2022 Jan;74(1):18-47. doi: 10.1124/pharmrev.121.000381.
6
Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.孕激素和催乳素调节的乳腺癌细胞基因表达的相互微调。
Mol Cell Endocrinol. 2020 Jul 1;511:110859. doi: 10.1016/j.mce.2020.110859. Epub 2020 May 11.
7
Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.醋酸乌利司他抑制孕激素受体A亚型介导的人乳腺癌增殖及Bcl-2-L1表达。
PLoS One. 2015 Oct 16;10(10):e0140795. doi: 10.1371/journal.pone.0140795. eCollection 2015.
8
Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects.肝细胞癌中的孕激素及相关化合物:基础与临床方面。
Biomed Res Int. 2013;2013:290575. doi: 10.1155/2013/290575. Epub 2013 Jan 16.
9
Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study.雌激素与人孕酮受体A和B单体的亲和力及乳腺癌风险:一项比较分子模拟研究。
Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 8.